Advertisement
The Company intends to immediately file for Phase 3 clinical testing withthe People's Republic of China's State Food and Drug Administration after theannouncement of the findings from Phase 2 testing. The Company anticipatesthat the Chinese government will then allow for the commencement of Phase 3testing within two to three months after the Phase 2 results are published.Phase 3 testing will entail large-volume tests on over 300 patients and is thelast step before it may be commercially sold in the People's Republic ofChina.
Advertisement
About Rh-Apo2L- The Anti-Cancer Drug
Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treatcertain forms of cancer. This biopharmaceutical drug has gained the attentionof researchers and clinical professionals throughout the People's Republic ofChina who are observing the drug for potential replacement of surgery andradiation therapy for cancer. Potentially, over 8 million lives can be savedeach year in the People's Republic of China by this drug.
About Aida Pharmaceuticals
Aida Pharmaceuticals is a product-focused pharmaceuticals company engagedin the formulation, clinical testing, registration, manufacture, sales andmarketing of advanced pharmaceutical and genetic products in mainland China.The Company's mission is to discover, develop and market meaningful newtherapies that improve human health. Aida Pharmaceuticals, in operation sinceMarch 1999, is headquartered in Hangzhou, China with manufacturing,distribution and sales points throughout mainland China. Aida is GMPcertified in China and ISO9002 certified for quality assurance and ISO14000certified for ecologically-friendly practices.
Safe Harbor Statement Under The Private Securities Litigation Reform Actof 1995: Except for historical information contained herein, the statementsin this news release are forward-looking statements that are made pursuant tothe safe harbor provisions of the Private Securities Litigation Reform Act of1995. Forward-looking statements involve known and unknown risks anduncertainties, which may cause a company's actual results, performance andachievement in the future to differ materially from forecasted results,performance, and achievement. These risks and uncertainties are described inthe Company's periodic filings with the Securities and Exchange Commission.The Company undertakes no obligation to publicly release the result of anyrevisions to these forward-looking statements that may be made to reflectevents or circumstances after the date hereof, or to reflect the occurrence ofunanticipated events or changes in the Company's plans or expectations.For additional information, please visit http://en.aidapharma.com. Contact Information: Ashley Hull (310) 450-9100 opt 1 [email protected] Broker Contact: Chesapeake Group (410) 825-3930
SOURCE Aida Pharmaceuticals, Inc.
